Eli Lilly’s diabetes and weight-loss drug Mounjaro debuts in India
Investing.com -- U.S. pharmaceutical company Eli Lilly (NYSE: LLY) has introduced its diabetes and weight-loss drug Mounjaro in India, ahead of its competitor Novo Nordisk (NYSE: NVO ). This comes as India, the world’s most populous country, faces rising levels of obesity and diabetes.
It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug ...
We recently published a list of 8 Best Robinhood Stocks to Buy According to Analysts. In this article, we are going to take a ...
Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and it's an element you can count on ...
Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...
Eli Lilly stock has generated fantastic returns for ... The company has a couple of GLP-1-approved drugs in Zepbound (weight loss) and Mounjaro (diabetes), and the billions in revenue these ...
Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. And retail traders should know. We ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback